Latest news

• EMA recommends heart risk restriction for Servier's Protelos

  That review brought restrictions that included a prohibition on the use of Protelos' in immobilised patients or patients with a history of venous thromboembolism (VTE). ... This time around the PRAC wants the EMA's Committee for Medicinal Products for

• Process for NICE guidance re-evaluation

  Servier Laboratories, the licence holder of Protelos (strontium ranelate), which instigated the review, remains satisfied with Mr Holman's judgement that NICE acted with procedural unfairness, and therefore unlawfully, by not

• High Court rules against NICE in osteoporosis case

  The High Court has ruled that NICE must look again at its decision not to fund the use of osteoporosis drug Protelos on the NHS. ... The High Court has ruled that the National Institute for Health and Clinical Excellence (NICE) must look again at its

• R&D News in brief

  Protelos shines in study. Servier's osteoporosis treatment, Protelos, is effective in reducing nonvertebral and vertebral fractures over five years, according to two new studies presented at the Sixth European Congress ... One trial of 1649

• Food for thought

  Protelos - for osteoporosis. As a passionate believer in the relevant unexpected, I suppose this ad is totally relevant in its visual context but not entirely unexpected - unless one expects to see